FTI Starts to Accumulate FLASH Coin and Issues Director Stock Options
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- FTI Foodtech International Inc. (TSXV:FTI) ("FTI" or the "Company") announces that, the Company has made an initial purchase of 2 million FLASH coin. This initial purchase of 1,967,691 FLASH coin will be used to establish a link between existing barter markets and FLASH coin.
Additionally, in an effort to attract and retain quality board members, on May 18, 2018, the Company issued a total of 700,000 director stock options, each at $0.20 with a three-year expiry of May 18, 2021. All previously outstanding options have been exercised by the date of this release.
Other than mentioned above, there are no material changes with the Company.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, contact: William Hullah, President, FTI at (416) 444-1058.
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as...
Today, NOQX announces that they have successfully secured their first round of funding from an impressive group of investors. Of note is Phillip Chambers, founder...
Pipedrive, the easy and effective sales CRM for small businesses, is launching Pipedrive AI, a broad range of AI tools powered by OpenAI and internally developed AI software engines. The new product suite aims to take the manual work out of sales,...
As GROWMARK, Inc. continues to position itself to lead in the digital agronomy space, it has partnered with Intelinair, an ag data analytics company, on a new digital agronomy application to equip its farmer customers with data-driven insights to...
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...
